Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Covington
Deloitte
Baxter
Medtronic
Boehringer Ingelheim
Teva
Federal Trade Commission
Citi
Argus Health

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208026

« Back to Dashboard

NDA 208026 describes JENTADUETO XR, which is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are sixteen patents protecting this drug. Additional details are available on the JENTADUETO XR profile page.

The generic ingredient in JENTADUETO XR is linagliptin; metformin hydrochloride. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.
Summary for 208026
Tradename:JENTADUETO XR
Applicant:Boehringer Ingelheim
Ingredient:linagliptin; metformin hydrochloride
Patents:16
Formulation / Manufacturing:see details
Pharmacology for NDA: 208026
Ingredient-typeBiguanides
Mechanism of ActionDipeptidyl Peptidase 4 Inhibitors
Suppliers and Packaging for NDA: 208026
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0270 0597-0270-12 1 BOTTLE in 1 CARTON (0597-0270-12) > 14 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE
JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0270 0597-0270-73 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0597-0270-73)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength2.5MG;1GM
Approval Date:May 27, 2016TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Apr 24, 2017Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
Patent:➤ SubscribePatent Expiration:Sep 19, 2016Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATING TYPE 2 DIABETES
Patent:➤ SubscribePatent Expiration:Jun 20, 2020Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 208026

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026-002 May 27, 2016 ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026-001 May 27, 2016 ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026-002 May 27, 2016 ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026-001 May 27, 2016 ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026-001 May 27, 2016 ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026-002 May 27, 2016 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
US Department of Justice
Cipla
QuintilesIMS
Farmers Insurance
Citi
Deloitte
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot